Fragile X syndrome (FXS) is the most frequent form of inherited intellectual disability and is also linked to other neurologic and psychiatric disorders. FXS is caused by a triplet expansion that inhibits expression of the FMR1 gene; the gene product, FMRP, regulates mRNA metabolism in the brain and thus controls the expression of key molecules involved in receptor signaling and spine morphology. While there is no definitive cure for FXS, the understanding of FMRP function has paved the way for rational treatment designs that could potentially reverse many of the neurobiological changes observed in FXS. Additionally, behavioral, pharmacological, and cognitive interventions can raise the quality of life for both patients and their families.
"fmr1 [fragile X mental retardation 1] knockout mice, Black and Tan BRachyury (BTBR) mice, and valproic acid-treated rats), that display autistic-like features. Fragile X syndrome (FXS) is an inherited disorder caused by mutations in the fmr1 gene, that is translated into the fragile X mental retardation 1 protein (FMRP), that in turn plays a role in the development of synapses  . Expansion mutations of the fmr1 gene produce autistic features in approximately 40% of FXS patients, and thus FXS provides a valuable model for identifying novel biomarkers/targets for autism and for dissecting the underlying neurochemical pathways . "
[Show abstract][Hide abstract] ABSTRACT: Autism spectrum disorder (ASD) is a complex behavioral condition with onset during early childhood and a lifelong course in the vast majority of cases. To date, no behavioral, genetic, brain imaging, or electrophysiological test can specifically validate a clinical diagnosis of ASD. However, these medical procedures are often implemented in order to screen for syndromic forms of the disorder (i.e., autism comorbid with known medical conditions). In the last 25 years a good deal of information has been accumulated on the main components of the "endocannabinoid (eCB) system", a rather complex ensemble of lipid signals ("endocannabinoids"), their target receptors, purported transporters, and metabolic enzymes. It has been clearly documented that eCB signaling plays a key role in many human health and disease conditions of the central nervous system, thus opening the avenue to the therapeutic exploitation of eCB-oriented drugs for the treatment of psychiatric, neurodegenerative, and neuroinflammatory disorders. Here we present a modern view of the eCB system, and alterations of its main components in human patients and animal models relevant to ASD. This review will thus provide a critical perspective necessary to explore the potential exploitation of distinct elements of eCB system as targets of innovative therapeutics against ASD.
Journal of the American Society for Experimental NeuroTherapeutics 07/2015; DOI:10.1007/s13311-015-0371-9 · 5.05 Impact Factor
"repressor and thereby regulates activity-dependent translation of a number of mRNAs (Brown et al., 2001; Akins et al., 2009, 2012; Strumbos et al., 2010; Zhang et al., 2012). Additionally, FMRP is believed to selectively bind approximately 4% of all mRNAs in the mammalian brain, many of which are known to code for proteins involved in neuronal maturation and synaptic plasticity (Brown et al., 2001; Till, 2010; Bagni et al., 2012). The absence of FMRP (in humans and Fmr1 KO animals) results in dysregulated translation of select mRNAs, abnormal synaptic function, dendritic dysmorphology characteristic of immature neurons, and a loss of protein synthesis-dependent plasticity leading to disordered expression of normally regulated proteins (Rudelli et al., 1985; Hinton et al., 1991; Comery et al., 1997; Irwin et al., 2000; Nimchinsky et al., 2001; Galvez et al., 2003; Pfeiffer and Huber, 2009; Zhang et al., 2009; Strumbos et al., 2010; Deng et al., 2011). "
"Otro síntoma importante asociado con FXS es la ansiedad. La ínsula parece estar implicado en la representación de experiencias adversivas como el miedo y la ansiedad (Bagni et al., 2012; Paulus & Stein, 2006). "
[Show abstract][Hide abstract] ABSTRACT: Fragile X syndrome in humans is caused by a mutation in the FMR1 gene and it is associated with severe mental retardation, hyperactivity and anxiety. Here we compare FMR1 Knock-Out mice, a model of Fragile-X syndrome, and wild-type mice with respect to the neuronal density of the insular cortex, a brain area associated with pain processing and anxiety management. Mice were also subjected to a spatial learning test in an anxiogenic environment. Results show significant asymmetry between neuronal density between left and right insula in knock out as compared to wild type mice. Behaviorally, although knock-out mice did not show deficits in task completion they explored the maze at a higher velocity than their wild-type counterparts. Furthermore, insular density asymmetry correlated with higher velocity during one of the spatial navigation tasks at the individual mouse level. These results suggest that insular neuronal density asymmetry in FMR1 Knot-Out mice may be considered as an anatomical correlate of the observed behavioral abnormalities.
International Journal of Morphology 12/2014; 32(4):1377-1382. · 0.32 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.